Showing 4821-4830 of 6059 results for "".
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem
- New Research Shows How Immune Cells Organize Themselves in the Epidermishttps://practicaldermatology.com/news/new-research-shows-how-immune-cells-organize-themselves-in-the-epidermis/2460827/New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. Many people don’t realize that the epidermis is home to immune cells. To bring more cla
- AADA Statement on Legislative Interference in Health Care for Transgender Patientshttps://practicaldermatology.com/news/aada-statement-on-legislative-interference-in-health-care-for-transgender-patients/2460817/The American Academy of Dermatology Association strongly opposes recent efforts by state legislatures to restrict physicians’ ability to provide care to transgender youths. Legislation such as the bill enacted this spring in Arkansas as well as those proposed in several other states are a d
- Cosentyx Now Approved for Psoriasis in Children as Young as Sixhttps://practicaldermatology.com/news/cosentyx-now-approved-for-psoriasis-in-children-as-young-as-six/2460815/Cosentyx® (secukinumab) from Novartis is now FDA approved for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the U
- AAD Survey: Americans Are Confused About Sunscreen Usehttps://practicaldermatology.com/news/aad-survey-americans-are-confused-about-sunscreen-use/2460812/Your patients likely need a refresher course on sunscreen application and SPF. This is the main takeaway message of a recent survey of 1,000 U.S. adults by the American Academy of Dermatology. While 80 percent of Americans know they should apply sunscreen every two hours when outdoors,
- Indoor Tanning Linked to Anxiety, Depressionhttps://practicaldermatology.com/news/indoor-tanning-linked-to-anxiety-depression/2460808/Indoor tanning early in life is associated with risk of anxiety and depression later in life, according to new research in the Journal of the American Academy of Dermatology. Excluding women wi
- Medivir’s Remetinostat Shows Promise for SCChttps://practicaldermatology.com/news/medivirs-remetinostat-shows-promise-for-scc/2460807/Topical remetinostat gel performed well in a small investigator-initiated phase II clinical study of patients with squamous cell carcinoma. Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumors, including
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas
- Curcumin Nanoparticles May Be Viable Adjuvant for Sunscreenhttps://practicaldermatology.com/news/curcumin-nanoparticles-may-be-viable-adjuvant-for-sunscreen/2460803/Curcumin may be a viable photoprotective adjuvant when delivered through nanoparticles, according to research published by a collaborative team from the George Washington University (GW) School of Medicine and Health Sciences (SMHS) Department of Dermatology and Albert Einstein College of Medicin
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pr